The molecular alterations in tumour cells leading to resistance towards apoptosis induced by CD95 and TRAIL-receptors are not fully understood. We report here that the stimulation of the CD95-and TRAILresistant human pancreatic adenocarcinoma cell line PancTuI with an agonistic anti-CD95 antibody or TRAIL resulted in activation of protein kinase C and NF-kB. Inhibition of protein kinase C by GoÈ 6983 sensitized these cells to apoptotic challenges and strongly diminished activation of NF-kB by anti-CD95 and TRAIL. Similarly, inhibition of NF-kB by MG132 or by transient transfection with a dominant negative mutant of IkBa restored the responsiveness of PancTuI cells to both death ligands. In the CD95 and TRAILsensitive cell line Colo357 the induction of protein kinase C and NF-kB following activation of CD95 and TRAIL-R was very moderate compared with PancTuI cells. However, pre-incubation of these cells with PMA strongly reduced their apoptotic response to anti-CD95 and TRAIL. Taken together, we show that activation of protein kinase C operates directly in a death receptordependent manner in PancTuI cells and protect pancreatic tumour cells from anti-CD95 and TRAILmediated apoptosis by preventing the loss DCm and Cytochrome c release as well as by induction of NF-kB. Oncogene (2001) 20, 4258 ± 4269.
Introduction
In addition to perturbations in cell cycle control, resistance to apoptosis may promote tumour growth and metastasis. The acquisition of an apoptosisresistant phenotype by tumour cells may also upset the success of conventional radio-and chemotherapies. Apoptosis resistance mechanisms seem to vary among dierent tumour types and have only begun to be characterized at the molecular level. In vivo, life/death decisions are regulated by the death receptors TNF-R1, CD95 (Fas, APO-1), TRAIL-R1 (DR4), TRAIL-R2 (DR5) and their cognate death ligands TNFa, CD95 ligand and TRAIL (APO-2L), respectively (Wiley et al., 1995; Pitti et al., 1996; Peter et al., 1998; Pan et al., 1997; Walczak et al., 1997) . Ligand binding to CD95 and TRAIL-R is followed by recruitment of proapoptotic adaptor molecules such as TRADD and FADD to their intracellular death domain and subsequent binding of FLICE/caspase-8 to FADD completing formation of the`death-inducing signaling complex' (DISC) (Krammer, 1999) . In the case of CD95, caspase-8 is thought to activate downstream caspases either directly (type I cells) or via activation of the mitochondrial pro-apoptotic machinery (type II cells) eventually resulting in apoptosis . Using the pancreatic adenocarcinoma as a model system, we have shown earlier that the vast majority of established cell lines are refractory to anti-CD95 stimulation despite CD95 expression on the cell surface (Ungefroren et al., 1998) . Several intracellular proteins may inhibit apoptosis by interfering with death receptor signal transduction either at the DISC (FLIPs) (Irmler et al., 1997; Leverkus et al., 2000) or mitochondrial (Bcl-2, Bcl-x L ) level (Reed, 1998) . Protein kinase C (PKC) has been shown to regulate apoptosis induced by various stimuli (Scadi et al., 1999; Jamieson et al., 1999; Sawai et al., 1997; Kobayashi et al., 1997) . Furthermore, it has been demonstrated that stimulation of CD95 selectively inhibits certain PKC-isoforms in CD95-sensitive Jurkat T cells (Chen and Faller, 1999) . Pre-treatment of these cells with the broad spectrum PKC-activator PMA strongly reduced the apoptotic response of these cells to anti-CD95. Similarly, pre-treatment of CD95-sensitive colon carcinoma cells with PMA impaired their sensitivity to anti-CD95-induced apoptosis (von Reyher et al., 1998) . Notably, PMA-activated PKC was shown to protect only type II cells from CD95-induced apoptosis which implies that PKC targets proteins involved in the mitochondrial pro-apoptotic pathway (Scadi et al., 1999) . However, until now no data are available on the involvement of PKC in TRAIL-mediated apoptosis.
Several members of the PKC family are capable of inducing nuclear translocation of NF-kB (Sanz et al., 1999) . Anti-neoplastic drugs that induce PKC activity prevent drug-induced apoptosis through the activation of NF-kB (Kumuda and White, 1997) . NF-kB also plays an important role in tumorigenesis consistent with the aberrant expression and activity of members of the Rel/NF-kB family in several tumour types (Rayet and Celinas, 1999) . Inhibition of NF-kB sensitized cells to TNFa-mediated apoptosis (Barket and Gilmore, 1999; Beg and Baltimore, 1996) . Similarly, both TRAIL-R1 and TRAIL-R2 can induce NF-kB activation through TRAF/NIK proteins (Chaudhary et al., 1997) and the inhibition of NF-kB augmented TRAIL-mediated apoptosis in haemopoietic cells (Kupatt et al., 1998) . Engagement of CD95 does not seem to involve the recruitment of TRAF proteins (Nagata, 1997) , yet in some cell types activation of NF-kB following stimulation of CD95 was reported (Malinin et al., 1997; Packham et al., 1997) . However, its role as an apoptosis protection factor is still a matter of controversy (Kupatt et al., 1998; Ponton et al., 1996) . In the present study we investigated the role of PKC and NF-kB in CD95-and TRAIL-R-mediated apoptosis of pancreatic adenocarcinoma cells.
Results
Recently, we reported that pancreatic adenocarcinoma cell lines PancTuI and Colo357 dier in their sensitivity to anti-CD95-and TRAIL-induced apoptosis despite expression of comparable amounts of CD95, TRAIL-R1 and TRAIL-R2 on the cell surface (Ungefroren et al., 1998; Hinz et al., 2000) . We showed that PancTuI cells are almost completely resistant, wheras Colo357 are moderately sensitive to anti-CD95 and highly sensitive to TRAIL. Since it had been suggested that TRAIL-R3 (Degli-Esposti et al., 1997b) and TRAIL-R4 (Degli-Esposti et al., 1997a) may protect cells from TRAIL-mediated apoptosis, we additionally analysed expression of these receptors on PancTuI and Colo357 cells and found that both cell lines do not express detectable levels of TRAIL-R3 and TRAIL-R4 (data not shown). Moreover, the expression of FLIP ( Figure  1 ) which can modulate the apoptotic sensitivity by aecting the DISC formation are comparable in PancTuI and Colo357 cells.
From these observations we conclude that the dierence in the apoptotic response of these cells to anti-CD95 and TRAIL is more likely caused by speci®c apoptosis resistance mechanisms downstream of the receptor level. These persist or are induced upon ligand binding and block CD95-and TRAIL-mediated apoptosis in PancTuI and, partially, CD95-mediated apoptosis in Colo357 cells.
PKC protects pancreatic tumour cells from CD95-and TRAIL-mediated apoptosis
Since it has been reported that PKC can play a protective role in apoptosis, we investigated whether the inhibition of PKC restored the sensitivity of PancTuI cells to anti-CD95 or TRAIL. Figure 2a shows that incubation of PancTuI cells with the PKC inhibitor GoÈ 6983 given prior to (left panel) or simultaneously with (right panel) anti-CD95 or TRAIL resulted in signi®cant augmentation of apoptotic cell death. GoÈ 6983 itself was not toxic to the cells. These results were con®rmed by analysis of PARP-cleavage demonstrating that caspase 3 was activated by the combined treatment of cells with GoÈ 6983 and either anti-CD95 or TRAIL (Figure 2a, inset, lanes 5+6) . Similarly, inhibition of PKC by GoÈ 6983 was still able to potentiate the apoptotic response of Colo357 cells to both death-inducing agents (Figure 2b) .
Furthermore, the pre-treatment of Colo357 cells with PMA, a well established PKC activator, strongly reduced the sensitivity of these cells to anti-CD95 and TRAIL-induced DNA fragmentation (Figure 2c ; left panel). Under these conditions, strong inhibition of PARP cleavage could be observed as compared to cells exposed to TRAIL or CH11 without PMA pretreatment (Figure 2d ). These results suggest that activation of PKC by PMA is able to protect the otherwise sensitive Colo357 cells from apoptosis by blocking caspase 3 activation. Interestingly, treatment of Colo357 cells with PMA following (15 min) exposure to TRAIL or CH11 failed to protect these cells from apoptosis ( Figure 2c ; right panel).
Recently, we showed that endogenous (PancTuI cells) or transduced Bcl-x L (Colo357 cells) partially protected these cell lines from anti-CD95 and TRAIL induced apoptosis (Hinz et al., 2000) , classifying both cell lines as Type II cells. We thus further examined the nor Colo357 cells with PMA was able to modulate TRAIL-induced Bid cleavage. Moreover, the kinetics and eciency of Bid cleavage in TRAIL-resistant PancTuI cells was nearly identical as in TRAILsensitive Colo357 cells. Additional investigations on caspase 9 revealed that in Colo357 cells anti-CD95 as well as TRAIL both eciently activated caspase 9, consistent with their apoptosis inducing capacity in these cells. Again, PMA was able to diminish the extent of caspase 9 cleavage which may explain inhibited caspase 3 activation shown in Figure 2d . In contrast, caspase 9 activation was achived in PancTuI cells only following the combined treatment with PKC inhibitor GoÈ 6983 and either anti-CD95 or TRAIL (Figure 3) . 
Activation of PKC is an intrinsic feature of stimulated CD95 and TRAIL receptors
Since PancTuI cells were almost completely refractory to anti-CD95-and TRAIL-mediated apoptosis and the inhibition of PKC partially restored their sensitivity to both death-inducing agents, we examined the possibility that stimulated CD95 and TRAIL receptors activate PKC in these cells. Figure 5a shows that both death receptors activated PKC (1.7-and 1.9-fold, respectively) following ligand binding. Consistent with the observation that Colo357 cells were sensitive to anti-CD95-and TRAIL-induced cell death, stimulation of both receptors induced PKC activity to a lesser extent than in PancTuI cells (1.3-and 1.15-fold, respectively; Figure 5b ). Taken together, these ®ndings suggest a correlation of the dierent apoptotic response status of PancTuI and Colo357 cells to the levels of PKC activation by both death receptors.
Constitutive expression of PKC isoforms in PancTuI and Colo357 cells
The family of PKCs consists of several members, for some of which the pro-or anti-apoptotic function has been documented. In order to narrow down the choice of the PKC isoforms that could protect PancTuI cells PancTuI and Colo357 cells were exposed for indicated time periods to anti-CD95 (100 ng/ml) or TRAIL (100 ng/ml) with or without pre-treatment with GoÈ 6983 (10 mM) or PMA (100 nM) respectively. Whole cell lysates (RIPA) were separated in 15% (caspase 8 and Bid) or 12.5% SDS ± PAGE and analysed in Western blot using antibodies against caspase 8, Bid and caspase 9. As control the level of b-actin was also determined from death receptor mediated apoptosis we compared the basal levels of PKC a, b, d, e, g, Z, i, m, y and z expression in Colo357 and PancTuI cells. PKC g, Z and x were not detectable in both cell lines, data not shown. Figure 6 shows that only expression of PKCm was much stronger in the resistant PancTuI cells.
PKC is involved in the induction of NF-kB after exposure of PancTuI cells to anti-CD95 and TRAIL
Since some isoforms of PKC are capable of inducing NF-kB (Sanz et al., 1999) , we next investigated whether the engagement of CD95 and TRAIL For determination of Cytochrome c release cells were exposed for indicated time periods to TRAIL (100 ng/ml) or anti-CD95 (100 ng/ml) with or without pre-incubation with PMA (100 nM, Colo357; a and b) or Go È 6983 (10 mM, PancTuI; c and d). Equal amounts of cytoplasmic extracts, prepared as described in`Apoptosis assays', were separated in 15% SDS ± PAGE and analysed by Western blot using anti-Cytochrome c and anti-b-actin antibodies receptors induced NF-kB activity. Electrophoretic mobility shift assays (EMSAs) were performed with nuclear extracts from PancTuI cells treated for various time periods with anti-CD95 or TRAIL. As shown in Figure 7a , both agents induced nuclear NF-kB activity detectable after 15 min and down-regulated after 3 h (anti-CD95) or detectable after 30 min and persisting for at least 6 h (TRAIL). As demonstrated by supershift assays in cells stimulated with anti-CD95 or TRAIL, the activated NF-kB form represents the p65/ p50 heterodimer as well as p50/p50 homodimer ( Figure  7b) . Similarly, exposure of Colo357 cells to anti-CD95 or TRAIL resulted in NF-kB induction but in contrast to PancTuI the nuclear binding activity of NF-kB in the case of TRAIL was transient and occurred later (1 h) (Figure 7c) .
If the activation of PKC by death receptors causes the induction of NF-kB, an inhibition of PKC should diminish the activation of NF-kB after exposure of PancTuI cells to anti-CD95 and TRAIL. Using nuclear protein extracts from PancTuI cells treated with CH11 or TRAIL with or without pre-treatment with GoÈ 6983, gel shifts with radioactively labeled NF-kB consensus oligonucleotides were performed. As shown in Figure  7d , GoÈ 6983 strongly reduced the amount of p65/p50 complexes in the nuclei from PancTuI cells treated with anti-CD95 or TRAIL. The same results were obtained when PancTuI cells were exposed to GoÈ 6983 and anti-CD95 or TRAIL simultaneously (data not shown). These results indicate a crucial role of PKC in NF-kB activation by anti-CD95 and TRAIL in these cells.
Inhibition of NF-kB sensitizes pancreatic tumour cells to anti-CD95 and TRAIL-mediated apoptosis
To investigate whether the activation of NF-kB protected PancTuI cells from anti-CD95-and TRAIL-induced apoptosis, we used two approaches to inhibit NF-kB activity. As shown in Figure 8a , pretreatment of cells with MG132, an inhibitor of the 26S proteasome known to degrade IkB, strongly reduced the nuclear binding activity of NF-kB induced by anti-CD95 and TRAIL. The same results were obtained when PancTuI cells were exposed to MG132 and anti-CD95 or TRAIL simultaneously (data not shown). In the presence of MG132 given prior to (Figure 8b (Figure 8c) . Similarly, treatment of Colo357 cells with MG132 still increased the sensitivity of these cells to both death ligands (Figure 8d ). Since the members of the IAP family (inhibitors of apoptosis), consisting of several direct inhibitors of caspases, have been shown to be induced by NF-kB, we investigated whether the expression of c-IAP1, c-IAP2 and XIAP is aected by treatment of PancTuI cells with anti-CD95 and TRAIL. Figure 9 demonstrates that c-IAP1 and XIAP levels were transiently elevated by both, anti-CD95 and TRAIL, whereas c-IAP2 was not induced following CD95-ligation and even down-regulated after TRAIL-receptor stimulation.
Taken together, the data presented here show that PKC can interfere with early apoptotic signal transduction of both CD95 and TRAIL receptors in two ways: inhibition of the mitochondrial pathway by blocking both Cytochrome c release and the loss of DCm and by activation of NF-kB. Figure 5 Eect of the stimulation of CD95 or TRAIL-R on PKC activity. PancTuI (a) or Colo357 (b) cells were exposed for 5, 10, 15, 30 and 45 min to either anti-CD95 mab CH11 (100 ng/ ml) or TRAIL (100 ng/ml). Protein lysates were analysed for the activity of PKC as described in Materials and methods. Data shown are representative results from four independent experiments performed in triplicate (+s.d.)
Discussion PKC is involved in the regulation of apoptosis acting either as a promoter (Bharti et al., 1998) or an inhibitor (Kobayashi et al., 1997; Kumuda and White, 1997) . Anticancer drugs can induce NF-kB as part of an anti-apoptotic pathway through the activation of PKC (Kumuda and White, 1997). In the case of CD95-dependent apoptosis, the protective function of PKC has been demonstrated in CD95-sensitive Jurkat T cells in which pre-treatment with PMA protected these cells from apoptosis (Scadi et al., 1999) . Moreover, selective inhibition of PKC isoforms was shown to be part of a pro-apoptotic pathway induced by stimulated CD95 in these cells (Chen and Faller, 1999) . Notably, PMA-mediated protection from CD95-induced apoptosis occurred only in type II cells, e.g. Jurkat cells, by inhibition of Bid cleavage (Scadi et al., 1999) . We showed that PMA pre-treatment inhibited apoptosis of the CD95-and TRAIL-sensitive pancreatic adenocarcinoma cell line Colo357 through prevention of the loss of DCm and Cytochrome c release. These results are in agreement with our recent data identifying Colo357 as type II cells in both the CD95 and the TRAIL system, based on the ®nding that Bcl-x L eectively protected these cells from anti-CD95 and TRAIL-induced apoptosis (Hinz et al., 2000) . However, in contrast to Colo357 cells, PancTuI cells were resistant to CD95-and TRAIL-mediated apoptosis. In this cell line PKC was activated directly in response to engagement of both death receptor pathways and protected these cells from apoptosis, at least partially, by activation of NFkB and by inhibition of Cytochrome c release and the loss of DCm. To our knowledge, this is the ®rst report Figure 6 Constitutive expression of PKC isoforms in Colo357 and PancTuI cells. 30 mg of whole cell lysates from 70 ± 80% con¯uent Colo357 and PancTuI cells were analysed in Western blot for the expression of PKC isoforms using anti-PKC antibodies. As reference 30 mg of Jurkat T cells lysates and when available the positive control was analysed in parallel. To con®rm the equal loading of the gel the expression of b-actin was determined demonstrating the existence of a protective pathway in CD95-and TRAIL-R-signal transduction that involves PKC-mediated NF-kB activation and inhibition of the mitochondrial apoptosis pathway. Since TRAIL strongly activated NF-kB in Colo357 cells despite a very weak PKC induction, a PKC-independent pathway of NF-kB activation by TRAIL-receptors obviously exists. Our data are consistent with the observation that TRAIL is able to induce NF-kB (Chaudhary et al., 1997) and are novel as they show for the ®rst time that inhibition of NF-kB can restore the sensitivity of epithelial tumour cells to TRAILmediated apoptosis comparable to ®ndings with various lymphoid cell lines (Kupatt et al., 1998) . Unlike the situation in the TRAIL system, induction of NF-kB and its putative eect on the execution of CD95-dependent apoptosis are still a matter of controversy. It has been reported that engagement of CD95 induced activation of NF-kB in some cell lines irrespective of their sensitivity to apoptosis (Ponton et al., 1996) . By contrast, CD95-sensitive Jurkat cells did not only fail to activate NF-kB after CD95 ligation but in fact repressed it during the early steps of apoptosis through proteolytic degradation of p65 and p50 proteins (Ravi et al., 1998) . One possible explanation for these discrepancies is that the repertoire of proteins recruited by stimulated CD95 is cell type speci®c and among others may involve certain PKC isoforms that are present in pancreatic tumour cells such as PancTuI but absent or downregulated in other cell types. Another possibility is that the rapid induction of NFkB after engagement of CD95 is unable to protect cells from apoptosis if NF-kB downstream pathways are repressed. The inhibition of PKC by CD95 ligation in Jurkat cells may also explain the failure of NF-kB induction in these cells and, in our system, the failure of the apoptosis protective potential of PMA when added to Colo357 cells after exposure to TRAIL or anti-CD95. Several studies show that some isoforms of PKC are able to activate NF-kB (Sanz et al., 1999) . Since both proteins are repressed during the very early steps of apoptosis in CD95-sensitive Jurkat cells, it seems possible that the mechanisms controlling this repression are inactivated in CD95-resistant PancTuI cells and partially inhibited in moderately sensitive Colo357 cells. Serine/threonine protein phosphatases were postulated to inhibit PKC after CD95 ligation (Chen and Faller, 1999) and may also be involved in the signaling pathways of activated TRAIL receptors.
The detailed mechanism(s) by which activated PKC inhibits the disruption of mitochondria in CD95 and TRAIL-resistant pancreatic tumour cells remain(s) to be elucidated. An attractive target in the case of CD95-mediated apoptosis is the BH3 protein Bid. Interest- ingly, no in¯uence of PKC activation on Bid cleavage after TRAIL-R stimulation could be observed. Moreover, PKC seems to protect pancreatic tumour cells from TRAIL-mediated apoptosis with lower eciency than from apoptosis induced by stimulated CD95. It seems therefore possible that some dierences in the apoptotic pathways induced by TRAIL and anti-CD95 exist and additional PKC target molecules protect from TRAIL-mediated apoptosis. The PKC isoforms activated by death receptors in PancTuI or by PMA in Colo357 cells which may be responsible for establishing the resistant phenotype remain to be identi®ed. Our preliminary data suggest that PKCm could play this role: (i) PKCm is overexpressed in resistant PancTuI cells compared to sensitive Colo357 cells; (ii) the results from PKC inhibition studies using dierent PKC inhibitors (data not shown) revealed that only GoÈ 6983 and only in mM concentration was able to sensitize PancTuI cells to anti-CD95 and TRAIL. Gschwendt et al., 1996 reported that GoÈ 6983 inhibits several PKC isoforms in nM concentration and additionally PKCm only starting from mM concentration, thus allowing its dierentiation from other PKC isoenzymes. PKCm belongs to the PKC family members group which can be activated by PMA (Johannes et al., 1995) . Moreover, it has been shown that PKCm downregulates TNFa-mediated apoptosis by mechanisms involving the activation of NF-kB (Johannes et al., 1998) .
The NF-kB target genes interfering with apoptosis sensitivity in our system are unknown but likely candidates are the c-IAP1 and XIAP (Wang et al., 1998; Stehlik et al., 1998) since their expression was elevated in anti-CD95-or TRAIL-stimulated PancTuI cells.
In conclusion, we showed that PKC activity inhibits CD95 and TRAIL-induced apoptosis and that crosslinking of CD95 and TRAIL activates PKC which in turn triggers anti-apoptotic pathways, e.g. the inhibition of both the loss of DCm and Cytochrome c release from mitochondria and the induction of NF-kB in human pancreatic malignant epithelial cells.
Materials and methods

Cell lines and materials
Human pancreatic adenocarcinoma cell lines PancTuI and Colo357 were cultured in RPMI 1640 supplemented with 10% FCS, 2 mM glutamine and 1 mM sodium pyruvate (all from Life Technologies Inc., Karlsruhe, Germany). For the inhibition of NF-kB cells were treated with 2 mM MG132 (Biomol, Hamburg, Germany) or transiently transfected with an expression plasmid coding for the dominant negative IkBa mutant protein (DN-IkBa) kindly provided by Dr Florian Emmerich, Robert-RoÈ ssle Clinic, Humboldt University, Berlin, Germany. For stimulation of PKC, phorbol 12-myristate 13-acetate (PMA) was added to the medium (100 nM; Calbiochem, Bad Soden, Germany). To inhibit PKC, cells were treated with 10 mM GoÈ 6983 (Calbiochem). For the induction of death receptor mediated apoptosis, agonistic monoclonal anti-CD95-antibody CH11 (100 ng/ml; Coulter Immunotech, Hamburg, Germany) or recombinant TRAIL (100 ng/ml; R&D Systems GmbH, Wiesbaden, Germany) were added to the culture medium.
Transfection
PancTuI cells were grown in 6-well plates until 40 ± 60% con¯uence. The transient transfection was carried out using the Eectene Transfection Reagent (QIAGEN, Hilden, Germany) and 0.4 mg pCMV-DN-IkBa or 0.4 mg pCMVLacZ per well. After 24 h cells were exposed for additional 24 h to CH11 or TRAIL. The cell cycle analysis and cell death measurements were done by FACS (see Apoptosis assays).
PKC enzyme assays
PancTuI or Colo357 cells were cultured in 6-well plates in RPMI-medium containing 10% FCS until 50 ± 70% conuent, kept for 2 h serum-free and exposed to either 100 ng/ ml CH11 or 100 ng/ml TRAIL for 5 ± 45 min. Cells were lysed in 50 mM Tris-HCl (pH 7.5), 1% Triton X-100, 20 mM MgCl 2 , 150 mM NaCl, 5 mM EDTA, 10 nM okadaic acid and protease inhibitor cocktail (Amersham Pharmacia Biotech, Freiburg, Germany). The lysates were analysed in triplicate for PKC activity using the Biotrak protein PKC enzyme assay (Amersham Pharmacia Biotech) utilizing the PKC speci®c peptide substrate and the binding paper separation system which allows the separation of g-33 P-ATP labeled peptide from unincorporated label.
Western blot
To detect the cleavage products of PARP, cells were lysed in 62.5 mM Tris/HCl, pH 6.8; 6 M urea; 5% b-mercaptoethanol, sonicated for 15 s, incubated for 15 min at 658C and clari®ed by centrifugation. For detection of the expression of PKCIsoforms, IAPs, Bid, caspase 8, caspase 9 and û-actin cells were lysed in RIPA-buer. The lysates were separated on SDS-PAGE, blotted onto PVDF-membrane and incubated with the appropriate primary antibody followed by incubation with the HRP-conjugated secondary antibody (Amersham Pharmacia Biotech). Antigen visualization was performed by enhanced chemiluminescence (ECL-kit, Amersham Pharmacia Biotech). Primary antibodies used were purchased from: anti-PARP-mab (Ab-2, Calbiochem), anti-PKC-a, b, d, e, g, Z, i, y (Transduction Laboratories), antiPKCm (Santa Cruz Biotechnology), anti-PKCz (Alexis Biochemicals), anti-c-IAP1, c-IAP2, XIAP and FLIP (R&D Systems), anti-Bid (Santa Cruz Biotechnology), anti-caspase 8 and anti-caspase 9 (StressGen Biotechnology, Canada), bactin (Sigma, Germany).
Apoptosis assays
For detection of apoptosis, two assays measuring DNAfragmentation, were employed. Additionally, the speci®c cleavage of PARP was analysed (see Western blotting). The JAM assay was performed as recently described (Ungefroren et al., 1998) . The percentage of speci®c DNA fragmentation, indicating a reduction of target cell viability, was calculated as: percent apoptosis=1007(E/S)6100, where E (experimental) is c.p.m. of retained DNA in the presence of apoptosis-inducing agent under study and S (spontaneous) is c.p.m. of retained DNA of untreated control cells. (100 ng/ml) or TRAIL (100 ng/ml) were resolved in 10% SDS ± PAGE, blotted onto PVDF-membrane and detected with anti-XIAP, anti-c-IAP1 or anti-c-IAP2 antibody. Equal loading of the gel was determined by analysis of the b-actin content For¯ow cytometric analysis (FACScan) of apoptosis, cells were stained with propidium iodide and analysed using the Becton Dickinson FACScan¯ow cytometer and the`Cell Quest' program as described previously (SchaÈ fer et al., 1999) . Data were expressed as percentage of overall cell counts.
To determinate the mitochondrial integrity, the loss of the mitochondrial membrane potential DCm was measured using the ApoAlert Mitochondrial Membrane Sensor Kit (Clontech, Heidelberg, Germany) followed by FACScan analysis.
For analysis of Cytochrome c release 7610 5 cells were washed twice with PBS, resuspended in 80 ml of an ice-cold lysis buer (20 mM HEPES pH 7.5, 10 mM KCl, 1.5 mM MgCl 2 , 1 mM EDTA, 1 mM DTT), incubated for 15 min on ice and subsequently lysed by passing 10 times through a 26-gauge needle. The extracts were clari®ed by centrifugation at 16 000 g for 30 min and stored at 7808C. 25 ml of the lysates were loaded on 15% SDS ± PAGE. Detection of Cytochrome c was performed as described in`Western blot'.
Electrophoretic mobility shift assay (EMSA)
For detection of the activation of NF-kB, nuclear extracts were prepared as described (SchaÈ fer et al., 1998) and incubated in EMSA-buer (Promega, Mannheim, Germany) with a g 32 P-labeled oligonucleotide 5'-AGTTGAGGG-GACTTTCCCAGGC-3' containing a consensus NF-kB binding site (Promega). After 30 min at room temperature samples were submitted to native PAGE run at 100 V and 48C. Gels were dried and exposed to X-ray Hyper®lm (Amersham). For supershift assay, 0.4 mg of anti-p65 or 0.4 mg of anti-p50 antibodies (both from Santa-Cruz) were added to the sample and incubated for the additional 1 h at 48C. For competition assays, an 50-fold excess of unlabeled speci®c NF-kB oligonucleotides or 100-fold excess of unlabeled unspeci®c CREB-binding sequence containing oligonucleotides (Promega) were added to cell extracts 10 min prior to the incubation with labeled NF-kB binding oligonucleotides.
Abbreviations EMSA, electrophoretic mobility shift assay; FACS,¯uor-escence activated cell sorting; FADD, Fas-associated death domain protein; IAP, inhibitor of apoptosis; IkB, inhibitory kB; mab, monoclonal antibody; NF-kB, nuclear factor -kB; PARP, poly(ADP-ribose) polymerase; PKC, protein kinase C; PMA, phorbol 12-myristate 13-acetate; PVDF, polyvinylidene di¯uoride; TRAIL-R, tumour necrosis factor-related apoptosis inducing ligand-receptor.
